WYNNEFIELD CAPITAL INC
Long book
$147.5M
Q1 2026
Positions
9
Top-10 weight
100%
concentration
Last quarter
-2.7%
SPY +14.8%
Turnover
25%
of book per quarter
Strategy in plain words
auto-generated from filingsWYNNEFIELD CAPITAL INC is a concentrated fundamental stock-picker, specialised in healthcare (77% of the long book), running a $147.5M US long book across 9 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: NATURES SUNSHINE PRODS INC, CADRE HOLDINGS INC, DLH HOLDINGS CORP, LIFECORE BIOMEDICAL INC, AGNICO EAGLE MINES LTD.
Over the last 9 quarters its long book ran on average 4.8pp per quarter behind the S&P 500, beating the index in 2 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-11.2%
Q2 2024
+1.7%
Q3 2024
+0.2%
Q4 2024
-11.9%
Q1 2025
+14.3%
Q2 2025
+6.0%
Q3 2025
+12.5%
Q4 2025
-11.5%
Q1 2026
-2.7%
Sector allocation
Healthcare 77%
Services media 15%
Materials 5%
Utilities 2%
Industrials 1%
Long book by quarter
What does WYNNEFIELD CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| NATR NATURES SUNSHINE PRODS INC | Healthcare | 2.5M | $59.3M | 40.2% | Held |
| CDRE CADRE HOLDINGS INC | Healthcare | 1.1M | $35.3M | 23.9% | +13.9% |
| DLHC DLH HOLDINGS CORP | Services media | 3.7M | $21.4M | 14.5% | Held |
| LFCR LIFECORE BIOMEDICAL INC | Healthcare | 4.7M | $17.5M | 11.9% | Held |
| AEM AGNICO EAGLE MINES LTD | Materials | 35.0K | $7.1M | 4.8% | Held |
| QRHC QUEST RESOURCE HOLDING CORP | Utilities | 2.7M | $3.3M | 2.2% | Held |
| TPCS TECHPRECISION CORP | Industrials | 433.6K | $1.3M | 0.9% | Held |
| NNBR NN INC | Industrials | 28.1K | $41K | 0.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 9 | $147.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 12 | $177.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 15 | $166.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 15, 2025 | 16 | $169.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 16 | $158.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 16 | $219.4M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 17 | $224.7M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 17 | $222.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 23 | $251.7M | canonical | SEC ↗ |